Join Growin Stock Community!

Alterity therapeutics limitedATHE.US Overview

US StockHealthcare
(No presentation for ATHE)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ATHE AI Insights

ATHE Overall Performance

ATHE AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ATHE Recent Performance

-1.60%

Alterity therapeutics limited

0.05%

Avg of Sector

-0.31%

S&P500

ATHE PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ATHE Key Information

ATHE Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ATHE Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Price of ATHE

ATHE FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ATHE Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.85
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
11.47
PB Ratio
2.14
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
96.04%
Net Margin
-446.68%
Revenue Growth (YoY)
-46.73%
Profit Growth (YoY)
-46.58%
3-Year Revenue Growth
-33.77%
3-Year Profit Growth
-34.48%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.85
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
11.47
PB Ratio
2.14
Price-to-FCF
-
Gross Margin
96.04%
Net Margin
-446.68%
Revenue Growth (YoY)
-46.73%
Profit Growth (YoY)
-46.58%
3-Year Revenue Growth
-33.77%
3-Year Profit Growth
-34.48%

  • When is ATHE's latest earnings report released?

    The most recent financial report for Alterity therapeutics limited (ATHE) covers the period of 2025Q4 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ATHE's short-term business performance and financial health. For the latest updates on ATHE's earnings releases, visit this page regularly.

  • How much debt does ATHE have?

    As of the end of the reporting period, Alterity therapeutics limited (ATHE) had total debt of 155.46K, with a debt ratio of 0. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ATHE have?

    At the end of the period, Alterity therapeutics limited (ATHE) held Total Cash and Cash Equivalents of 33.16M, accounting for 0.72 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.